BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells

Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint

(2022) Zhen-Hua Wu et al.   Journal for ImmunoTherapy of Cancer

Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils

(2022) Leonie M. Behrens et al.   Cancers

ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer

(2022) Rodney Cheng-En Hsieh et al.   Science Immunology

Phase 1 Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

(2021) Stephen M Ansell et al.   CLINICAL CANCER RESEARCH

Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells

(2021) Gabriela Andrejeva et al.   JOURNAL OF IMMUNOLOGY

Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis

(2021) Roarke A. Kamber et al.   NATURE

Intratumoral SIRPα-deficient macrophages activate tumor antigen-specific cytotoxic T cells under radiotherapy

(2021) Zhen Bian et al.   Nature Communications

Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-Alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

(2021) Paolo Strati et al.   BLOOD

Targeting the cluster of differentiation 47/signal-regulatory protein alpha axis in myeloid malignancies

(2021) Chen Wang et al.   CURRENT OPINION IN HEMATOLOGY

Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study

(2021) Nehal J Lakhani et al.   LANCET ONCOLOGY

SIRPγ-CD47 Interaction Positively Regulates the Activation of Human T Cells in Situation of Chronic Stimulation

(2021) Safa Dehmani et al.   Frontiers in Immunology

Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study

(2021) Christiane Querfeld et al.   Lancet Haematology

Targeting macrophage checkpoint inhibitor SIRPα for anticancer therapy

(2020) Jie Liu et al.   JCI Insight

Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance

(2020) Vanessa Gauttier et al.   JOURNAL OF CLINICAL INVESTIGATION

Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity

(2020) Darienne R. Myers et al.   Frontiers in Immunology

Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity

(2020) Tracy C. Kuo et al.   Journal of Hematology & Oncology

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

(2019) Branimir I. Sikic et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα

(2019) Janet Sim et al.   mAbs

Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint

(2019) Erik Voets et al.   Journal for ImmunoTherapy of Cancer

Anti-human SIRPα antibody is a new tool for cancer immunotherapy

(2018) Yoji Murata et al.   CANCER SCIENCE

SIRPα–CD47 Immune Checkpoint Blockade in Anticancer Therapy

(2018) André Veillette et al.   TRENDS IN IMMUNOLOGY

Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis

(2018) Hanke L. Matlung et al.   Cell Reports

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

(2018) Ranjana Advani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein α Signaling

(2017) Meng Michelle Xu et al.   IMMUNITY

The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer

(2017) Hanke L. Matlung et al.   IMMUNOLOGICAL REVIEWS

Shp1 function in myeloid cells

(2017) Clare L. Abram et al.   JOURNAL OF LEUKOCYTE BIOLOGY

SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin

(2017) Jun Chen et al.   NATURE

Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity

(2017) Nan Guo Ring et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding

(2016) Penka S. Petrova et al.   CLINICAL CANCER RESEARCH

Exclusive transmission of the embryonic stem cell-derived genome through the mouse germline

(2016) Frank Koentgen et al.   GENESIS

Durable antitumor responses to CD47 blockade require adaptive immune stimulation

(2016) Jonathan T. Sockolosky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect

(2015) David J. DiLillo et al.   CELL

CD47 blockade triggers T cell–mediated destruction of immunogenic tumors

(2015) Xiaojuan Liu et al.   NATURE MEDICINE

Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential

(2015) Jie Liu et al.   PLoS One

Complement in Antibody-Based Tumor Therapy

(2014) Stefanie Derer et al.   CRITICAL REVIEWS IN IMMUNOLOGY

Polymorphisms in the Human Inhibitory Signal-regulatory Protein α Do Not Affect Binding to Its Ligand CD47

(2014) Deborah Hatherley et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Macrophages eliminate circulating tumor cells after monoclonal antibody therapy

(2014) Nuray Gül et al.   JOURNAL OF CLINICAL INVESTIGATION

The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target

(2013) A. Neil Barclay et al.   Annual Review of Immunology

Neutrophils mediate antibody-induced antitumor effects in mice

(2013) M. Albanesi et al.   BLOOD

Distinct Roles for Neutrophils and Dendritic Cells in Inflammation and Autoimmunity in motheaten Mice

(2013) Clare L. Abram et al.   IMMUNITY

Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys

(2013) Maya K Leabman et al.   mAbs

Engineered SIRP  Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies

(2013) K. Weiskopf et al.   SCIENCE

Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47

(2012) David R Soto-Pantoja et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond

(2012) P. Mark Hogarth et al.   NATURE REVIEWS DRUG DISCOVERY

CD47-signal regulatory protein-  (SIRP ) interactions form a barrier for antibody-mediated tumor cell destruction

(2011) X. W. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

(2010) Mark P. Chao et al.   CELL

Thrombospondin-1 Inhibits VEGF Receptor-2 Signaling by Disrupting Its Association with CD47

(2010) Sukhbir Kaur et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Endothelial CD47 interaction with SIRP  is required for human T-cell transendothelial migration under shear flow conditions in vitro

(2008) M. Stefanidakis et al.   BLOOD

Paired Receptor Specificity Explained by Structures of Signal Regulatory Proteins Alone and Complexed with CD47

(2008) Deborah Hatherley et al.   MOLECULAR CELL